title: [Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD].
abstract: OBJECTIVE
  To report on the efficacy of intravitreal bevacizumab as off-label therapy in different angiographic subtypes in neovascular age-related macular degeneration (AMD).
  
  
  METHODS
  Seventy-five patients with neovascular AMD and recent disease progression were classified into different angiographic subtypes and were treated with intravitreal bevacizumab (1.25 mg/0.05 ml) at 6-week intervals. Patients with subfoveal classic choroidal neovascularization (CNV) also received photodynamic therapy. ETDRS visual acuity, ophthalmic exams, and optic coherence tomography (OCT) were performed before treatment, 1 week after treatment, and then on a 6-week basis. Fluorescein angiographies and medical check-ups were also done.
  
  
  RESULTS
  Bevacizumab led to stabilization of visual acuity (loss of less than 15 letters) in all angiographic subtypes during a follow-up of 37+/-13 weeks. Patients with occult extrafoveal CNV (n=6) profited the most and gained 2+/-2 lines. Treatment with intravitreal bevacizumab was very well tolerated in all patients, with neither systemic nor intraocular side effects, with the exception of one retinal pigment epithelium tear.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab treatment is efficacious in all angiographic CNV subtypes and leads to reduction of macular edema and stabilization or improvement in visual acuity.
authors.affiliation: Schwerpunkt Retinologie, Universitäts-Augenklinik, Im Neuenheimer Feld 400, 69120, Heidelberg, Deutschland.
authors.forename: K B
authors.initials: KB
authors.lastname: Schaal
authors.forename: C
authors.initials: C
authors.lastname: Engler
authors.forename: F
authors.initials: F
authors.lastname: Schütt
authors.forename: A
authors.initials: A
authors.lastname: Scheuerle
authors.forename: S
authors.initials: S
authors.lastname: Dithmar
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D010778:Photochemotherapy; D011183:Postoperative Complications / Q000175:diagnosis / Q000188:drug therapy; D012008:Recurrence; D012160:Retina / Q000187:drug effects / Q000473:pathology; D012163:Retinal Detachment / Q000175:diagnosis / Q000188:drug therapy; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab